Centre Jean Perrin
Clermont-Ferrand, France
52 recruiting
Showing 1–20 of 52 trials
Recruiting
Phase 3
Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Glioblastoma
Centre Oscar Lambret486 enrolled19 locationsNCT03663725
Recruiting
Phase 3
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Phase 3
Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers
Radiotherapy, AdjuvantOral Cavity CarcinomaFlap+1 more
Centre Francois Baclesse348 enrolled25 locationsNCT06798922
Recruiting
Phase 2
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
Prostate Cancer
Debiopharm International SA66 enrolled37 locationsNCT06395753
Recruiting
Not Applicable
Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Breast Cancer
Institut Claudius Regaud120 enrolled25 locationsNCT05378204
Recruiting
Not Applicable
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
Ovarian Cancer
Centre Jean Perrin55 enrolled1 locationNCT07361471
Recruiting
Phase 2
Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)
Low Grade Endometrial Stromal Sarcoma
Centre Leon Berard40 enrolled22 locationsNCT03624244
Recruiting
Phase 2
Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas
Squamous Cell Carcinoma of Head and Neck
Institut Claudius Regaud86 enrolled14 locationsNCT06557889
Recruiting
Phase 3
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma
Soft Tissue Sarcoma
Institut Claudius Regaud600 enrolled19 locationsNCT04307277
Recruiting
Not Applicable
Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
Soft Tissue SarcomaDesmoplastic Small Round Cell TumorClear Cell Sarcoma+7 more
Institut Claudius Regaud400 enrolled20 locationsNCT03967834
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 1Phase 2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 3
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3K27-alteredDiffuse Midline Glioma, H3 K27M-Mutant
Gustave Roussy, Cancer Campus, Grand Paris433 enrolled50 locationsNCT05476939
Recruiting
Not Applicable
Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)
Institut Curie450 enrolled13 locationsNCT06225505
Recruiting
Phase 2
A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Metastatic Renal Cell CarcinomaRadiotherapy
Centre Francois Baclesse77 enrolled30 locationsNCT04299646
Recruiting
Not Applicable
Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer
Gynecologic CancerRemission
Centre Francois Baclesse268 enrolled13 locationsNCT06553612